WHAT IS SEEKED TO BE PATENTED AS NOVEL & UNOBVIOUS IN LETTERS PATENT OF THE UNITED STATES IS:

- 1. (Canceled)
- 2. (Canceled)
- 3. (Canceled)
- 4. (Canceled)
- 5. (Canceled)
- 6. (Canceled)
- 7. (Canceled)
- 8. (Canceled)
- 9. (Canceled)
- 10. (Canceled)
- 11. (Canceled)
- 12. (Canceled)
- 13. (Canceled)
- 14. (Canceled)
- 15. (Canceled)
- 16. (Canceled)
- 17. (Canceled)
- 18. (Canceled)
- 19. (Canceled)
- 20. (Canceled)
- 21. (Canceled)
- 22. (Canceled)
- 23. (Canceled)
- 24. (Canceled)
- 25. (Canceled)
- 26. (Canceled)
- 27. (Canceled)
- 28. (Canceled)
- 29. (Canceled)
- 30. (Canceled)
- 31. (Canceled)
- 32. (Canceled)
- 33. (Canceled)
- 34. (Canceled)
- 35. (Canceled)
- 36. (Canceled)
- 37. (Canceled)
- 38. (Canceled)
- 39. (Canceled)
- 40. (Canceled)
- 41. (Canceled)
- 42. (Canceled)
- 43. (Canceled)
- 44. (Canceled)

- 45. (Canceled)
- 46. (Canceled)
- 47. (Canceled)
- 48. (Canceled)
- 49. (Canceled)
- 50. (Canceled)
- 51. (Canceled)
- 52. (Canceled)
- 53. (Canceled)
- 54. (Canceled)
- 55. (Canceled)
- 56. (Canceled)
- 57. (Canceled)
- 58. (Canceled)
- 59. (Canceled)
- 60. (Canceled)
- 61. (Canceled)
- 62. (Canceled)
- 63. (Canceled)
- 64. (Canceled)
- 65 (Canceled)
- 65. (Canceled)
- 66. (Canceled)
- 67. (Canceled)
- 68. (Canceled)
- 69. (Canceled)
- 70. (Canceled)
- 71. (Canceled)
- 72. (Canceled)
- 73. (Canceled)
- 74. (Canceled)
- 75. (Canceled)
- 76. (Canceled)
- 77. (Canceled)
- 78. (Canceled)
- 79. (Canceled)
- 80. (Canceled)
- 81. (Amended) An in vivo method of imaging a cancer of epithelial origin or cells expressing a polypeptide having the antibody binding specificity of the about 46 Kd differentiation Human Milk Fat Globule (HMFG) antigen, comprising

administering to a subject suspected of being afflicted with the cancer or carrying the cells an amount of a detectably labeled or unlabeled specifically targeted antibody, comprising a monoclonal antibody selectively binding a 46 Kd MW HMFG differentiation antigen that has an antigen affinity constant about 10^{10} - 10^{5} M⁻¹, and an agent comprising a detectable label, the antibody and the agent being operatively linked to one another, under conditions effective to deliver the antibody to target cells of epithelial origin carrying at least a portion of the 46Kd MW HMFG differentiation antigen in the subject's body to form antibody-cell antigen complexes;

administering to the subject a detectably labeled agent that binds the antibody at a site other than the 46 kDalton HMFG polypeptide binding site if the antibody is unlabeled; and detecting the presence of a label in the subject's body.

- 82. (Amended) The method of claim 81, wherein the antibody is administered intravenously, intraperitoneally, intracavitarily, intra-tumor, intramuscularly, or into the lymphatic system.
- 83. (Amended) The method of claim 81, wherein the labeled agent comprises a fuorescent or radiolabeled agent.
 - 84. (Amended) The method of claim 81, wherein

the antibody comprises an unlabeled antibody; and

the labeled agent comprises a labeled anti-antibody immunoglobulin, antibody binding fragment thereof, protein A, or Protein C.

85. (Amended) The method of claim 81, further comprising upon label detection the delivery of a therapeutic agent to target cancerous cells or cells of epithelial origin by

binding a therapeutic agent to the antibody of claim 81, at a site other than its antigen binding site;

administering to the subject a therapeutically effective amount of the antibody-bound therapeutic agent under conditions effective for the antibody to deliver the agent to the target cells; and

allowing the antibody to bind to the target cells, and the therapeutic agent to exert its effect on the cells.

86. (Canceled)

· • • •

- 87. (Canceled)
- 88. (New) The method of claim 81, wherein the labeled agent comprises a radionucleide, a fluorescent label, an enzyme or biotin.
- 89. (New) The method of claim 81, wherein the labeled agent is detected as a conjugate.
- 90. (New) The method of claim 89, wherein the antibody is conjugated to avidin, streptavidin, or a magnetic bead.
- 91. (New) The method of claim 81, wherein the antibody comprises a monoclonal antibody.
- 92. (New) The method of claim 81, wherein the antibody is provided as a composition with a non-proteolytic carrier.
- 93. (New) The method of claim 92, wherein the carrier comprises a biologically acceptable carrier.
- 94. (New) The method of claim 93, wherein the carrier comprises a pharmaceutically acceptable carrier.
- 95. (New) The method of claim 85, wherein the therapeutic agent comprises a radionucleide, an immmunotoxin, or an enzyme.
- 96. (New) The method of claim 85, wherein the antibody-therapeutic agent is delivered as a conjugate.
- 97. (New) The method of claim 96, wherein the antibody-therapeutic agent is conjugated to avidin, streptavidin, or a magnetic bead.
- 98. (New) The method of claim 85, wherein the antibody-therapeutic agent comprises a monoclonal antibody.

- 99. (New) The method of claim 85, wherein antibody-therapeutic agent is provided as a composition with a non proteolytic carrier.
- 100. (New) The method of claim 99, wherein the antibody-therapeutic agent carrier comprises a biologically acceptable carrier.
- (New) The method of claim 100, wherein the antibody-therapeutic agent carrier comprises a pharmaceutically acceptable carrier.